DMN:FRA
Diamyd Medical AB
0,069 €
arrow_downward
-0,72%(-0,00050) 1D
6 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,00 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,00 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
The Globe and Mail
·
45 րոպե առաջ
History Says Energy Led All Sectors in the Last Bear Market. Here's What's Different Now.
Yahoo Finance
·
15 ժամ առաջ
Tech stocks are now cheaper than the S&P 500 for the first time since 2017 — here's what history says comes next: Chart of the Day
AP News
·
1 օր առաջ
Carney welcomes Democrats’ push to end Trump’s tariffs on Canada after midterm victory
Bloomberg.com
·
1 օր առաջ
Anatomy of a Selloff: Sudden Chain Reaction Rattles Wall Street
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB